This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Winning ETF Strategies for Q4
by Sanghamitra Saha
The October-December period will revolve around the events like holiday season, presidential election, vaccine trials and stimulus talks.
ETFs to Minimize Volatility Amid Pausing Coronavirus Trials
by Sweta Jaiswal, FRM
Given the spike in coronavirus outbreak, dampened hopes of another economic stimulus and suspended vaccine and treatment trials, it seems investors might take refuge in low-volatility products.
Pandemic Surges, Stimulus Fades: ETF Strategies to Follow
by Sweta Killa
Volatility has once again been playing foul in the stock market due to resurgent COVID-19 infections and fading hopes of additional stimulus. Investors should follow some techniques to minimize volatility in their portfolio.
Factor & Smart Beta ETFs: What You Should Know
by Neena Mishra
We discuss factor investing and Q4 market outlook.
Defensive ETF Strategies for Q4 Amid Election Uncertainty
by Sweta Jaiswal, FRM
Let's look at some safer ETF strategies that investors can play keeping in mind certain burning issues that can cause increased uncertainty in the fourth quarter of 2020.
Minimize Volatility This Election Season With ETFs
by Sweta Jaiswal, FRM
Investors should prepare their portfolios for heightened volatility in the broader equities space in this year of U.S. Presidential elections.
ETF Strategies to Fight the Rising Coronavirus Fears
by Sweta Jaiswal, FRM
Investors seem to be increasingly worried about the worsening coronavirus situation globally and in the United States.
Bears Creep In: ETF Strategies to Win
by Sanghamitra Saha
Rising coronavirus cases in the United States and Europe, and talks of major banks involving in transferring illicit funds over decades weighed on investors??? sentiments to start the week.
No Rate Hike Until 2023: Here's How to Play With ETFs
by Sanghamitra Saha
As widely expected, the Fed held interest rates steady at a near-zero level in its latest meeting.
Why Is This the Right Time to Invest in Low-Volatility ETFs?
by Sanghamitra Saha
.S. markets may have bounced back at the news of AstraZeneca???s (AZN) resumption of its phase 3 trial, but gains have been limited as the fear factor remains in investors??? mind.